# US 2025/0205231 A1 · Tear Film Stability

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0205231 A1
- Document ID: US20250205231A1
- Status: Published application
- Kind: A1
- Application number: 19/077,241
- Filed: 2025-03-12
- Published: 2025-06-26
- Earliest claimed: 2012-02-02
- Inventors: Kenneth Gek-Jin OOI; Stephanie Louise WATSON
- Web page: https://patentgrep.com/patent/US20250205231A1

## CPC

- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 31/22: of acyclic acids, e.g. pravastatin
- A61K 31/225: Polycarboxylic acids
- A61K 31/351: not condensed with another ring
- A61K 31/366: having six-membered rings, e.g. delta-lactones
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/405: Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A61K 31/4418: having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A61K 31/4433: containing a six-membered ring with oxygen as a ring hetero atom
- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K 38/13: Cyclosporins
- A61P 3/06: Antihyperlipidemics
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 27/02: Ophthalmic agents
- A61P 27/04: Artificial tears; Irrigation solutions
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a method of stabilising a tear film in an individual having an ocular surface inflammatory disorder by providing a compound to an ocular surface of the individual to reduce the synthesis of a cholesterol by a meibum producing tissue.

## Claims

### Claim 1

A method of stabilising a tear film in an individual having an ocular surface inflammatory disorder including:
providing an individual having an ocular surface inflammatory disorder that is characterised by an unstable tear film, wherein the disorder is posterior blepharitis associated with meibomian gland dysfunction; and
providing a compound to an ocular surface of the individual to reduce the synthesis of a cholesterol by a meibum-producing tissue, wherein the compound is atorvastatin;
thereby stabilising the tear film in the individual,
wherein atorvastatin is applied in an amount equivalent to 1 to 15 drops per day from a 50 μM atorvastatin solution.

### Claim 2 (depends on 1)

The method of claim 1, wherein the application is for 1 to 4 weeks.

### Claim 3 (depends on 1)

The method of claim 1, further including the step of:
providing an anti-inflammatory compound and/or an immunosuppressant to an ocular surface of the individual.

### Claim 4 (depends on 3)

The method of claim 3, wherein the anti-inflammatory compound is a steroid.

### Claim 5 (depends on 4)

The method of claim 4, wherein the anti-inflammatory compound is selected from the group consisting of prednisolone, fluorometholone, triamcinolone, rimexolone, and betamethasone.

### Claim 6 (depends on 3)

The method of claim 3, wherein the immunosuppressant is a cyclosporin.

### Claim 7 (depends on 3)

The method of claim 3, wherein the atorvastatin and the anti-inflammatory compound and/or immunosuppressant are provided in separate dosage units.

### Claim 8 (depends on 1)

The method of claim 1, further including the step of:
providing an antibiotic to an ocular surface of the individual.

### Claim 9 (depends on 8)

The method of claim 8, wherein the antibiotics is bacteriostatic or bactericidal.

### Claim 10 (depends on 8)

The method of claim 8, wherein the antibiotic is bactericidal for Staphylococcus and Streptococcus species.
